Direct oral anticoagulant plasma levels and thrombin generation on ST Genesia system

Direct oral anticoagulant plasma levels and thrombin generation on ST Genesia system

Abstract Background Monitoring of anticoagulant activity of direct oral anticoagulants (DOACs) can be necessary in special situations. DOAC plasma levels have a high inter‐ and intraindividual variation and do not necessarily reflect the coagulation status of the patient. Thrombin generation (TG) is...

Descripció completa

Dades bibliogràfiques
Autors principals:	Christian Pfrepper, Michael Metze, Annelie Siegemund, Tristan Klöter, Thomas Siegemund, Sirak Petros
Format:	Article
Idioma:	English
Publicat:	Elsevier 2020-05-01
Col·lecció:	Research and Practice in Thrombosis and Haemostasis
Matèries:	anti‐Xa‐inhibitors correlation dabigatran DOAC plasma levels ST Genesia thrombin generation
Accés en línia:	https://doi.org/10.1002/rth2.12340

Ítems similars

Inhibition of thrombin generation 12 hours after intake of direct oral anticoagulants
per: Michael Metze, et al.
Publicat: (2020-05-01)

Thrombin generation measured on ST Genesia, a new platform in the coagulation routine lab: Assessment of analytical and between‐subject variation
per: Søren Risom Kristensen, et al.
Publicat: (2022-01-01)

Calibrated automated thrombogram II: removing barriers for thrombin generation measurements
per: P. L. A. Giesen, et al.
Publicat: (2021-08-01)

Factor Xa and thrombin induce endothelial progenitor cell activation. The effect of direct oral anticoagulants
per: Styliani Papadaki, et al.
Publicat: (2021-08-01)

The novel anticoagulants: entering a new era
per: Swiss Medical Weekly
Publicat: (2009-02-01)

Semi-automated thrombin dynamics applying the ST Genesia thrombin generation assay
per: Audrey Carlo, et al.
Publicat: (2022-07-01)

Direct oral anticoagulant blood level monitoring in daily practice
per: R. Bavalia, et al.
Publicat: (2021-05-01)

Anticoagulated patients exhibit intact endogenous thrombin potential using ST Genesia unlike the Calibrated Automated Thrombogram
per: Tuukka A. Helin, et al.
Publicat: (2021-03-01)

Thrombocytopenia induced by dabigatran: two case reports
per: Hyun Goo Kang, et al.
Publicat: (2017-06-01)

Serial thrombin generation and exploration of alternative anticoagulants in critically ill COVID-19 patients: Observations from Maastricht Intensive Care COVID Cohort
per: Tom W. van de Berg, et al.
Publicat: (2022-10-01)

Thrombin-induced platelet aggregation −effect of dabigatran using automated platelet aggregometry−
per: Mie Shimizu, et al.
Publicat: (2020-04-01)

Practical issues in measuring the anticoagulant effect of direct oral anticoagulants
per: Dopsaj Violeta
Publicat: (2020-01-01)

Dabigatran Plasma Measurement to Guide the Management of Acute Bleeding and Thrombotic Complications
per: Maurizio Tala, et al.
Publicat: (2018-09-01)

Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran
per: Jong-Min Kim, et al.
Publicat: (2022-01-01)

Direct oral anticoagulants in cirrhosis: Rationale and current evidenceKeypoints
per: Cindy Pereira Portela, et al.
Publicat: (2024-08-01)

Clinical characteristics of patients with direct oral anticoagulant (DOAC) levels outside expected ranges: A retrospective chart study
per: Dionne C.W. Braeken, et al.
Publicat: (2023-05-01)

Comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban in dogs
per: Alex M. Lynch, et al.
Publicat: (2024-11-01)

Direct oral anticoagulants; a review for the non-specialist
per: Thilina Gunawardena
Publicat: (2021-11-01)

Direct oral anticoagulant: Review article
per: Abdulrahman Nasiri, et al.
Publicat: (2022-01-01)

The new way of Dabigatran reversal – Idarucizumab
per: Erwin Ciechański, et al.
Publicat: (2019-02-01)

The new way of Dabigatran reversal – Idarucizumab
per: Erwin Ciechański, et al.
Publicat: (2019-02-01)

Hospital consumption of direct oral anticoagulants in regions of the Russian Federation in 2017–2022
per: A. V. Matveev, et al.
Publicat: (2024-01-01)

Effects of direct oral anticoagulants dabigatran and rivaroxaban on the blood coagulation function in rabbits
per: Yin Lu, et al.
Publicat: (2022-01-01)

Thrombin generation measurement using the ST Genesia Thrombin Generation System in a cohort of healthy adults: Normal values and variability
per: Sara Calzavarini, et al.
Publicat: (2019-10-01)

Distinct pleiotropic effects of direct oral anticoagulants on cultured endothelial cells: a comprehensive review
per: Natalia Atzemian, et al.
Publicat: (2023-09-01)

Dabigatran etexilate - A novel oral anticoagulant for bleeding complications
per: Himabindu Reddy, et al.
Publicat: (2015-09-01)

Effect of PCC on Thrombin Generation among Patients on Factor Xa Inhibitors with Major Bleeding or Needing Urgent Surgery (GAUGE): Design and Rationale
per: Shaw Shaw, et al.
Publicat: (2023-07-01)

Is There an Alternative Oral Anticoagulation to Vitamin-K-Antagonists for Patients with Mechanical Aortic Valve Replacement? – A Literature Review
per: Stephen Gerfer, et al.
Publicat: (2024-05-01)

Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants
per: Emmanuel J. Favaloro, et al.
Publicat: (2022-02-01)

Thrombin and factor Xa link the coagulation system with liver fibrosis
per: Ameet Dhar, et al.
Publicat: (2018-05-01)

An update on applications and limitations of direct oral anticoagulants
per: Sharon Wei, et al.
Publicat: (2023-04-01)

Analytical performance of the endogenous thrombin potential–based activated protein C resistance assay on the automated ST Genesia system
per: Laure Morimont, et al.
Publicat: (2022-03-01)

Direct Thrombin Inhibitor Dabigatran Compromises Pulmonary Endothelial Integrity in a Murine Model of Breast Cancer Metastasis to the Lungs; the Role of Platelets and Inflammation-Associated Haemostasis
per: Marta Smeda, et al.
Publicat: (2022-02-01)

Dabigatran mitigates cisplatin-mediated nephrotoxicity through down regulation of thrombin pathway
per: Mohamed Gamal El-Din Ewees, et al.
Publicat: (2021-07-01)

Reference values for thrombin dynamics in platelet rich plasma
per: Qiuting Yan, et al.
Publicat: (2021-02-01)

Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients
per: Jana Úlehlová, et al.
Publicat: (2021-11-01)

Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran
per: Maha Al-Ghafry, et al.
Publicat: (2022-10-01)

Dabigatran etexilate: a direct thrombin inhibitor
per: M. Dugnani
Publicat: (2013-05-01)

Safety of Dabigatran as an Anticoagulant: A Systematic Review and Meta-Analysis
per: Ya Zhou, et al.
Publicat: (2021-02-01)

Viscoelastometry for detecting oral anticoagulants
per: Philipp Groene, et al.
Publicat: (2021-03-01)